TPIMS to Provide Uniquely Focused Technology for NCI NExT Program
TPIMS' Dr. Richard Houghten and Dr. Greg Welmaker attended the kick-off meeting for the NCI Experimental Therapeutics (NExT) Program. The 22 selected centers from across the nation met in Bethesda, Maryland on June 23 & 24th to share information regarding their focused technology areas.
In 2016, the National Cancer Institute announced the renewal of the Chemical Biology Consortium (CBC), the discovery engine for the NCI Experimental Therapeutics (NExT) Program including the Torrey Pines Institute for Molecular Studies (TPIMS) as a Specialized Center. TPIMS is the first institute in Florida to be selected to participate in this program.
In April 2016, the CBC network was expanded from 12 to 22 centers, including 7 Dedicated Centers and 15 Specialized Centers, with world-class expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. The Dedicated Centers support the advancement of NExT discovery projects through all discovery stages and provide scientific leadership for the Consortium. The Specialized Centers provide uniquely focused technologies that facilitate the successful progression of NExT discovery projects at specific discovery stages.
The CBC operates as a collaborative network of 7 Dedicated (in blue on map) and 15 Specialized Centers (in pink on map). The Specialized Centers provide uniquely focused technologies that facilitate the successful progression of NExT discovery projects at specific discovery stages. http://next.cancer.gov/
Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.